A
BBIO icon

AlphaQuest’s BridgeBio Pharma BBIO Stock Holding History

AlphaQuest’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-696
Closed -$53.2K – 232
2025
Q4 		$53.2K Sell
696
-119
-15% -$7.81K ﹤0.01% 1926
2025
Q3 		$42.3K Buy
815
+585
+254% +$28.5K ﹤0.01% 1978
2025
Q2 		$9.93K Buy
+230
New +$8.37K ﹤0.01% 1856
2024
Q4 		– Sell
-31,173
Closed -$794K – 1718
2024
Q3 		$794K Buy
31,173
+17,849
+134% +$469K 0.07% 462
2024
Q2 		$337K Buy
+13,324
New +$364K 0.05% 602

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlphaQuest's BBIO Position: Q1 2026 in Review

AlphaQuest sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 696 shares — an estimated $53.2K sold.

AlphaQuest first reported a position in BBIO in Q2 2024 and held it in 5 quarters. The position peaked at $794K in Q3 2024. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • AlphaQuest reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 696 BridgeBio Pharma shares in Q1 2026, an estimated $53.2K.
  • AlphaQuest first reported a position in BridgeBio Pharma in Q2 2024 and held it in 5 quarters.
  • AlphaQuest's BridgeBio Pharma position peaked at $794K in Q3 2024.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.